Advertisement

Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A. Jones, Jennifer Woyach, Farrukh T. Awan, Kami J. Maddocks, Thomas Whitlow, Amy S Ruppert and John C. Byrd

Article Information

Citation 
vol. 128 no. 22 639

Print ISSN 
Online ISSN 
History 
  • Published online December 1, 2016.


Contributors 
  • Jeffrey A. Jones [MD MPH], 1Division of Hematology, The Ohio State University, Columbus, OH
  • Jennifer Woyach [MD], 1Division of Hematology, The Ohio State University, Columbus, OH
  • Farrukh T. Awan, 1Division of Hematology, The Ohio State University, Columbus, OH
  • Kami J. Maddocks [MD], 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
  • Thomas Whitlow [BA], 3Division of Hematology, The Ohio State University, Columbus,
  • Amy S Ruppert [MAS], 1Division of Hematology, The Ohio State University, Columbus, OH
  • John C. Byrd [MD], 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output